Received: 25 August 2020
Accepted: 6 January 2021
First Online: 14 January 2021
Ethics approval and consent to participate
: Institutional Review Board approval was obtained for access to the prospective observational database (Hackensack Meridian Health under Study# Pro2020–0342). The requirement for patient informed consent, verbal or written, and HIPAA aurthorization was waived by the IRB as this project represented a non-interventional study utilizing routinely collected data for secondary research purposes.
: Not applicable.
: <i>Potential conflicts of interest</i>: AHG reports being a study investigator for Genentech-Hoffman La Roche, during the conduct of the study; research funding as study investigator from Acerta, AstraZeneca, Celgene, Kite Pharma, Elsevier’s PracticeUpdate Oncology, Gilead, Medscape, MJH Associates, OncLive Peer Exchange, Physicians Education Resource, and Xcenda, outside the submitted work, and research funding as a study investigator for Constellation, Infinity, Infinity Verastem, Janssen, Karyopharm, and Pharmacyclics, outside of the submitted work.<i>Potential conflicts of interest:</i> EH report consulting for Regional Cancer Care Associates and Hackensack Meridian Health, outside the submitted work.<i>Potential conflicts of interest:</i> ALP and SLG report having equity ownership in COTA, outside the submitted work.<i>No conflicts of interest:</i> AI, JA, YZ, BAS, UB, MM, ISS, JPU, DMW, RP, RLS, MGP, SLC, FJC, AGC, BLP, DR, GEM, MPE, KLZ, and PM.